HRP20100673T1 - Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe - Google Patents
Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe Download PDFInfo
- Publication number
- HRP20100673T1 HRP20100673T1 HR20100673T HRP20100673T HRP20100673T1 HR P20100673 T1 HRP20100673 T1 HR P20100673T1 HR 20100673 T HR20100673 T HR 20100673T HR P20100673 T HRP20100673 T HR P20100673T HR P20100673 T1 HRP20100673 T1 HR P20100673T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- degree
- vaccine
- culture
- infectious agent
- Prior art date
Links
- 229960003971 influenza vaccine Drugs 0.000 title claims 2
- 230000003247 decreasing effect Effects 0.000 title 1
- 230000000642 iatrogenic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 7
- 229960005486 vaccine Drugs 0.000 claims abstract 6
- 244000052769 pathogen Species 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims abstract 3
- 238000012360 testing method Methods 0.000 claims abstract 3
- 210000003501 vero cell Anatomy 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims 6
- 241000709661 Enterovirus Species 0.000 claims 3
- 241000709664 Picornaviridae Species 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 239000012678 infectious agent Substances 0.000 claims 3
- 241000342334 Human metapneumovirus Species 0.000 claims 2
- 241000711504 Paramyxoviridae Species 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241001647378 Chlamydia psittaci Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241001533384 Circovirus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241001466953 Echovirus Species 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 244000309467 Human Coronavirus Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 241000351643 Metapneumovirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000711904 Pneumoviridae Species 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000702247 Reoviridae Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241001533467 Rubulavirus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000000751 protein extraction Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940031418 trivalent vaccine Drugs 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04255471 | 2004-09-09 | ||
| PCT/IB2005/003266 WO2006027698A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100673T1 true HRP20100673T1 (hr) | 2011-02-28 |
Family
ID=35520177
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100673T HRP20100673T1 (hr) | 2004-09-09 | 2010-12-06 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HR20110007T HRP20110007T1 (hr) | 2004-09-09 | 2011-01-05 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HRP20120640TT HRP20120640T1 (hr) | 2004-09-09 | 2012-08-07 | Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe |
| HRP20130962TT HRP20130962T1 (hr) | 2004-09-09 | 2013-10-10 | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110007T HRP20110007T1 (hr) | 2004-09-09 | 2011-01-05 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HRP20120640TT HRP20120640T1 (hr) | 2004-09-09 | 2012-08-07 | Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe |
| HRP20130962TT HRP20130962T1 (hr) | 2004-09-09 | 2013-10-10 | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8119337B2 (pt) |
| EP (5) | EP2179744B1 (pt) |
| JP (7) | JP2008512443A (pt) |
| AT (2) | ATE489965T1 (pt) |
| CA (2) | CA2579859C (pt) |
| CY (3) | CY1111180T1 (pt) |
| DE (3) | DE602005024827D1 (pt) |
| DK (4) | DK1789084T3 (pt) |
| ES (4) | ES2357747T3 (pt) |
| HK (2) | HK1105364A1 (pt) |
| HR (4) | HRP20100673T1 (pt) |
| PL (4) | PL1789084T3 (pt) |
| PT (4) | PT2578229E (pt) |
| RS (3) | RS51665B (pt) |
| SI (4) | SI1789084T1 (pt) |
| WO (1) | WO2006027698A1 (pt) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006027698A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Decreasing potential iatrogenic risks associated with influenza vaccines |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| CN104474543A (zh) * | 2005-11-01 | 2015-04-01 | 诺华疫苗和诊断有限两合公司 | 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗 |
| EP2368572B1 (en) | 2005-11-04 | 2020-03-04 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| KR20080069232A (ko) | 2005-11-04 | 2008-07-25 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼 |
| NZ592713A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| JP2009514850A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
| KR20110110853A (ko) | 2006-01-27 | 2011-10-07 | 노파르티스 파르마 아게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
| US20100068223A1 (en) | 2006-03-24 | 2010-03-18 | Hanno Scheffczik | Storage of Influenza Vaccines Without Refrigeration |
| AU2007245192B2 (en) | 2006-03-31 | 2012-04-12 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| WO2008059018A2 (en) * | 2006-11-15 | 2008-05-22 | Intervet International B.V. | Vaccine for vaccinating felines and canines against influenza virus |
| PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| EP2268309B1 (en) | 2008-03-18 | 2015-01-21 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
| EP2361304A2 (en) | 2008-11-05 | 2011-08-31 | GlaxoSmithKline Biologicals S.A. | Novel method |
| CA2752039A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| EA201500910A1 (ru) | 2009-02-10 | 2016-04-29 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
| WO2010092477A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
| DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| ES2813347T3 (es) | 2009-10-26 | 2021-03-23 | Wisconsin Alumni Res Found | Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| CA2797059A1 (en) * | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
| CA2800150C (en) | 2010-05-21 | 2018-09-04 | Novartis Ag | Influenza virus reassortment method |
| AU2011262312B2 (en) | 2010-06-01 | 2015-05-28 | Novartis Ag | Concentration and lyophilization of influenza vaccine antigens |
| DK2575872T3 (da) | 2010-06-01 | 2020-10-19 | Seqirus Uk Ltd | Koncentrering af influenzavaccineantigener uden frysetørring |
| GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| AU2011300402B2 (en) | 2010-09-07 | 2015-01-22 | Novartis Ag | Generic assays for detection of mammalian reovirus |
| EP2678452B1 (en) | 2011-02-25 | 2016-02-24 | Novartis AG | Exogenous internal positive control for virus detection |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| ES2564138T3 (es) * | 2011-12-12 | 2016-03-18 | Novartis Ag | Ensayo para Hemaglutinina del virus de la influenza |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| EP3764098B1 (en) | 2015-07-07 | 2022-11-16 | Seqirus UK Limited | Influenza potency assays |
| EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
| AU2018359556B2 (en) | 2017-11-03 | 2021-12-02 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| CN112912518A (zh) * | 2018-10-15 | 2021-06-04 | 再生生物股份有限公司 | 用于测量复制缺陷型病毒载体和病毒的感染性的方法 |
| WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| WO2020226831A1 (en) | 2019-05-08 | 2020-11-12 | Takeda Vaccines, Inc. | Inactivated virus compositions and zika vaccine formulations |
| EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
| EP4093415A1 (en) * | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized na |
| US20240139306A1 (en) * | 2021-03-01 | 2024-05-02 | Iowa State University Research Foundation, Inc. | Methods and compositions for detecting and producing porcine morbillivirus and vaccines thereof |
| CN114107392A (zh) * | 2021-11-22 | 2022-03-01 | 昆明理工大学 | 一种cvb5病毒类病毒样颗粒的制备方法 |
| WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193991A (en) | 1978-12-20 | 1980-03-18 | Cornell Research Foundation, Inc. | Canine parvovirus vaccine |
| EP0261955A3 (en) * | 1986-09-26 | 1989-06-07 | E.I. Du Pont De Nemours And Company | Process for immobilization of dna |
| US6284492B1 (en) * | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
| NZ240369A (en) | 1990-10-30 | 1993-09-27 | Daiichi Seiyaku Co | Muramyl dipeptide derivatives and vaccine compositions |
| JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン |
| IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
| CA2156525A1 (en) | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| DE4311580C1 (de) * | 1993-04-12 | 1994-08-18 | Werner Prof Dr Med Reutter | Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
| US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| DE69535940D1 (de) | 1994-11-10 | 2009-06-04 | Baxter Healthcare Sa | Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur |
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| JPH1175833A (ja) * | 1997-06-23 | 1999-03-23 | Chemo Sero Therapeut Res Inst | トリレオウイルスの調製法 |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| RU2000118777A (ru) * | 1997-12-11 | 2002-07-10 | Университи Оф Саскачеван (Ca) | Вирус синдрома мультисистемного истощения свиньи у поросят-отъемышей |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| DK1499348T3 (en) * | 2002-04-26 | 2015-01-05 | Medimmune Llc | PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| CN101058800B (zh) * | 2002-07-09 | 2013-03-13 | 巴克斯特国际有限公司 | 用于细胞培养的无动物蛋白质培养基 |
| JP3957188B2 (ja) * | 2002-10-25 | 2007-08-15 | ▲あき▼夫 友田 | 抗ウィルス剤 |
| US20040176272A1 (en) | 2003-01-30 | 2004-09-09 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
| CA2523319A1 (en) * | 2003-04-25 | 2004-11-11 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| WO2006027698A1 (en) * | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Decreasing potential iatrogenic risks associated with influenza vaccines |
| MX2009013628A (es) | 2007-06-14 | 2010-02-22 | Univ Oklahoma State | Vacunas que contienen variantes geneticas de parvovirus canino. |
-
2005
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en active Application Filing
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/en active Active
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es active Active
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es active Active
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de active Active
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es active Active
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/en not_active Revoked
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/en active Active
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es active Active
- 2005-09-09 RS RSP20110084 patent/RS51665B/en unknown
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 RS RS20120317A patent/RS52400B/en unknown
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/en not_active Revoked
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de active Active
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 RS RSP20110075 patent/RS51721B/en unknown
- 2005-09-09 EP EP05795012A patent/EP1789084B1/en active Active
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
-
2007
- 2007-11-26 HK HK07112869.6A patent/HK1105364A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 HK HK10109406A patent/HK1144374A1/xx not_active IP Right Cessation
- 2010-12-06 HR HR20100673T patent/HRP20100673T1/hr unknown
-
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
-
2012
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
-
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en active Active
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
-
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
-
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en active Active
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
-
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en active Active
-
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100673T1 (hr) | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe | |
| World Health Organization | WHO manual on animal influenza diagnosis and surveillance | |
| Pastoret | Human and animal vaccine contaminations | |
| JP2008512443A5 (pt) | ||
| JP2012025784A5 (pt) | ||
| Zhang et al. | Isolation of swine influenza virus in cell cultures and embryonated chicken eggs | |
| US20080193478A1 (en) | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus | |
| Pestka et al. | Occurrence, characteristics and control of pigeon paramyxovirus type 1 in pigeons | |
| US20180154004A1 (en) | Non-Gelatin Vaccine Protectant Composition and Live Attenuated Influenza Vaccine | |
| Choi et al. | Evaluation of transmission of swine influenza type A subtype H1N2 virus in seropositive pigs | |
| Zhang et al. | Isolation of swine influenza A virus in cell cultures and embryonated chicken eggs | |
| Madhi et al. | Evidence of human coroanvirus (229E), in patients with respiratory infection, Iran, 2015: the first report | |
| Velayudhan et al. | Human metapneumovirus in turkey poults | |
| Cliquet et al. | The fluorescent antibody virus neutralization test | |
| CN107267467B (zh) | 一种猪繁殖与呼吸综合征病毒的分离方法 | |
| CN107557346B (zh) | 一株h9亚型低致病性禽流感病毒及其应用 | |
| Wang et al. | Pathogenicity, immunogenicity, and protective ability of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein | |
| Gueriche et al. | The etiological role of the parainfluenza-3 virus in the respiratory pathology of young cattle | |
| Aoki et al. | Isolation of vaccine-derived measles viruses from children with acute respiratory infection | |
| Namroodi et al. | Frequency and antimicrobial resistance pattern of Salmonella Spp in asymptomatic rural dogs | |
| Manzoor et al. | Pathotyping of Newcastle disease virus using multiplex reverse transcription polymerase chain reaction and pathological studies in naturally infected broiler chicks | |
| CN105779376B (zh) | 一种流感病毒分离无血清培养基及其用途和制备 | |
| Intisar et al. | Isolation of some respiratory viruses from camels | |
| Hostnik et al. | Control of equine arteritis virus (EAV) on stud farm. | |
| Hopps et al. | Laboratory testing in rubella vaccine control |